Abstract
This Viewpoint reviews the mission of the proposed federal health research agency, explores its overlap with the National Institutes of Health, considers its congressional reception, and discusses its likely legislative vehicles.
Highlights
Intent on bolstering the “Beau Biden Cancer Moonshot” of the 21st Century Cures Act, President Biden has been advocating for an Advanced Research Projects Agency for Health (ARPA-H) within the US National Institutes of Health (NIH).[1]
The vetting of potential innovative projects by ARPA-H will not be the domain of academic peer reviewers as is the custom at the NIH
As articulated by Collins and colleagues, ARPA-H, modeled after its intrepid namesake, Defense Advanced Research Projects Agency (DARPA), is to “accelerate biomedical breakthroughs” and by so doing, “shape the future of health and medicine.”[2]. The ultimate success of ARPA-H will require that the program be afforded authority and independence, that managers be allowed to fail, that research targets be chosen wisely, and that the technologies developed be commercialized by industry.[3]
Summary
Intent on bolstering the “Beau Biden Cancer Moonshot” of the 21st Century Cures Act, President Biden has been advocating for an Advanced Research Projects Agency for Health (ARPA-H) within the US National Institutes of Health (NIH).[1]. As envisioned by the Biden administration, ARPA-H would be a semi-autonomous entity within the NIH and the US Department of Health and Human Services.
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call